Approval · Notice of Compliance 27675 · 2022
VIMOVO: Notice of Compliance 27675
Issued February 28, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27675
- Date
- February 28, 2022
- Company
- Xediton Pharmaceuticals Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
Products in this notice
Medicinal ingredients
- NAPROXEN 375 MG per TAB
- ESOMEPRAZOLE 20 MG per TAB
- NAPROXEN 500 MG per TAB